Department of Urologic Oncology, University of Colorado, Denver, CO, USA.
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):162-7. doi: 10.1038/pcan.2009.63. Epub 2010 Feb 2.
The aim of this study was to determine the treatment patterns and resource utilization of various prostate cancer treatments, and quantify the economic and clinical impact of each. In a retrospective analysis of medical and pharmacy claims between 2000 and 2005, using the PharMetrics database, male patients aged > or =40 years with prostate cancer diagnosis were identified. The costs of medical and prostate cancer-related expenditures for the treatment options were determined for three periods: from diagnosis to first treatment, during and after treatment. A total of 9035 patients were included. The mean age of patients diagnosed with prostate cancer was 61.4 years. Patients aged 50-59 years represented the highest proportion at 51%. The majority received some form of treatment. Watchful waiting (WW) was the primary means of management for 30%. The average 2-year cost for WW was $24 809 and for active treatment was $59, 286. Surgery was the most common treatment among younger men. Non-cancer-related costs were similar among those receiving treatment or WW, but prostate cancer costs were over five times greater in the treated patients. With or without treatment, prostate cancer is a significant clinical and economic burden to society. New strategies for treatment or cancer prevention could play a role in reducing this burden.
本研究旨在确定各种前列腺癌治疗方法的治疗模式和资源利用情况，并量化每种治疗方法的经济和临床影响。采用 PharMetrics 数据库，对 2000 年至 2005 年期间的医疗和药品索赔进行回顾性分析，确定了诊断为前列腺癌的男性患者的治疗方案的医疗和前列腺癌相关支出成本。将治疗选择的成本分为三个时间段进行评估：从诊断到首次治疗、治疗期间和治疗后。共纳入 9035 例患者。诊断为前列腺癌患者的平均年龄为 61.4 岁。50-59 岁的患者比例最高，为 51%。大多数患者接受了某种形式的治疗。观察等待（WW）是 30%患者的主要管理方法。WW 的平均 2 年成本为 24809 美元，积极治疗的成本为 59286 美元。手术是年轻男性最常见的治疗方法。接受治疗或 WW 的患者的非癌症相关成本相似，但治疗患者的前列腺癌成本是 WW 患者的五倍以上。无论是否接受治疗，前列腺癌都是对社会的重大临床和经济负担。新的治疗或癌症预防策略可能在减轻这一负担方面发挥作用。
